Thuốc Benlysta

Chia sẻ: Nguyen Uyen | Ngày: | Loại File: PDF | Số trang:4

Thêm vào BST

Báo xấu

138
lượt xem 3
download

Download Vui lòng tải xuống để xem tài liệu đầy đủ

Thuốc Benlysta (Human Genome Sciences and GlaxoSmithKline) thử nghiệm trị bệnh Lupus Scheduled for a March 10 approval, Benlysta could be the first new lupus drug developed in 50 years. It isn't a cure. Taken monthly, the intravenous drug prevents flare-ups by inhibiting B-cells found in the immune system, which in lupus patients attack the body and organs. Lupus isn't easy to treat, which explains why Benlysta has received widespread attention and why Human Genome Sciences' stock price has skyrocketed over the last two years. ...

Chủ đề:

Bình luận(0) Đăng nhập để gửi bình luận!

Lưu

Nội dung Text: Thuốc Benlysta

Thuốc Benlysta Thuốc Benlysta (Human Genome Sciences and GlaxoSmithKline) thử nghiệm trị bệnh Lupus Scheduled for a March 10 approval, Benlysta could be the first new lupus drug developed in 50 years. It isn't a cure. Taken monthly, the intravenous drug prevents flare-ups by inhibiting B-cells found in the immune system, which in lupus patients attack the body and organs. Lupus isn't easy to treat, which explains why Benlysta has received widespread attention and why Human Genome Sciences' stock price has skyrocketed over the last two years. Regulators have concerns about Benlysta's long-term effectiveness and the drug's effectiveness on African Americans. The FDA has delayed approval once already. Thuốc Ipilimumab (Bristol-Myers Squibb) thử nghiệm trị Ung thư da melanoma, Ung thư nhiếp hộ tuyến và ung thư phổi
Also referred to by the brand name Yervoy, ipilimumab improves survival for people with a deadly form of skin cancer by stimulating the immune system to fight cancer cells. In a study released in June, 45.6% of advanced melanoma patients taking ipilimumab after failing to respond to chemotherapy were alive after a year. That's a big deal. Available treatments work poorly, and once melanoma spreads survival averages six to nine months. The drug's side effects can be severe. Bristol-Myers, meanwhile, is testing ipilimumab on earlier stages of melanoma, as well as prostate and lung cancer. An FDA decision is due by March 26. Thuốc Telaprevir (Vertex Pharmaceuticals and Johnson & Johnson) thử nghiệm ngăn ngừa siêu vi trùng viêm gan C phát triển Big expectations for the hepatitis C drug helped to fuel Vertex's share price over the last several years. The drug prevents the hepatitis C virus from reproducing and can eventually eliminate it faster than current therapies.
That's welcome news for the 3.9 million Americans infected with the virus, which causes liver damage. Current treatments take months and cure far fewer patients, leaving them to face worsening health problems. Telaprevir could receive FDA approval in May, along with a similar drug from Merck & Co. Thuốc INCB18424 (Incyte and Novartis) thử nghiệm trị bệnh Myelofibrosis, những bệnh rối loạn máu, bệnh vẩy nến và ung thư Known simply as INCB18424, Incyte's compound could be the first treatment approved by the FDA for myelofibrosis, a rare and often fata l disorder that scars bone marrow so it can't manufacture blood cells. The drug isn't a cure. It reduces swelling of the spleen and other symptoms. Meanwhile, it's being tested on other blood disorders, as well as psoriasis and cancer. Incyte's application should arrive at the FDA in the next few months. If the agency fast tracks their review, a decision is possible before year end.
Thuốc Xarelto (Johnson & Johnson and Bayer) thử nghiệm ngăn ngừa đông máu, ngừa đông máu khi giải phẫu những bệnh xương hay do bệnh rung tâm nhĩ (Atrial fibrillation) Also known as rivaroxaban, Xarelto made our list in 2009 and 2010. But the drug ran into delays at the FDA. Still, it could be the first in a new class of blood-clot-preventing drugs to hit the U.S., with approval expected late this year. Already available in Europe and Canada, Xarelto rivals Coumadin and its generic, warfarin, which prevent stroke but require frequent blood tests. Xarelto was initially intended to prevent strokes in patients undergoing orthopedic surgery, but J&J is also seeking approval for atrial fibrillation (an irregular heart rhythm). .. all five drugs hold promise, offering patients … reasons to hope. Dược sĩ Trịnh Nguyễn Đàm Giang